Pfizer takeover could delay drug development, says Astra chief

 

AstraZeneca Chief Executive Pascal Soriot: "The risk associated with any large merger is disruption"

Related Stories

The chief executive of AstraZeneca has warned that new drug development could be hit if it were taken over by Pfizer.

Pascal Soriot told MPs that a takeover would create huge disruption and distraction as scientists worried about their futures rather than development.

However, Business Secretary Vince Cable later told the Business Committee that blocking a bid could be "tricky".

The committee is taking evidence on the proposed takeover amid worries about the damage it could do to UK interests.

Earlier, Pfizer's chief Ian Read told the MPs that his company was not a ruthless cost-cutter, and said the drugmaker acted with "integrity".

He repeated assurances that Pfizer would protect jobs and investment, but admitted that a merger would mean a reduction in the combined companies' spending on research and development.

Uncertainty

Even though no formal offer from US-based Pfizer has been tabled, the proposed £63bn-plus takeover has generated huge controversy. The Commons Science Committee will hold its own hearing on Wednesday.

Mr Soriot told the Business Committee that the uncertainty created by a takeover could undermine some of AstraZeneca's work.

Start Quote

We are a highly ethical company. Pfizer is a company that keeps its promises”

End Quote Ian Read Chief executive, Pfizer

"Any distractions on work we are doing now could run the risk of delaying our drugs pipeline," he said. "From the lab to the patient takes many years.

"What will we tell the person whose father died from lung cancer because one of our medicines was delayed because our companies were involved in saving taxes or saving costs?

"It is logical to assume that a merger like this could mean substantial cost savings, and cost savings could mean job losses," he said.

Mr Soriot said the re-domiciling of the newly-merged company to the UK - which Pfizer has said would still see its headquarters remain in New York - would cause "substantial controversy", likely to result in delays.

However, he said that it would be the board of Astra's duty to consider a formal offer from Pfizer, despite rebuffing the US drugmaker's approaches so far.

Chief executive of Pfizer Ian Read: "I think the commitment of 20% of a global company's R&D in the UK is an unprecedented commitment"

"It's impossible to say we would never accept any offer," he told a committee. "We are very well aware of our fiduciary duty."

Limited powers

However, despite demands that the government should either block the bid or secure legal guarantees on jobs and investment, Mr Cable told the committee that intervention was "tricky".

The UK has public interest laws governing certain takeovers, such as those involving defence and media interests, but not for science.

Mr Cable said: "The framework which we have under the act, as you know, confines the public interest test quite narrowly and, of course, all of that takes place within the framework of European merger law."

For anyone in the pharmaceutical industry, the Holy Grail is the discovery of what they call a new "molecule", a cleverly-designed compound that proves effective as a treatment.

But achieving this is fiendishly complicated - getting approval has become hugely expensive and success is far from guaranteed.

AstraZeneca itself has a long history of developing new molecules to tackle everything from high blood pressure to breast cancer and the UK scientific community is rightly proud of that.

But less obvious amid the current war of words is that four of the company's most promising drugs are in its hands, not because of homegrown research, but because AstraZeneca acquired them when it bought a US firm called MedImmune.

One of these drugs is MEDI4736, not a name that trips off the tongue, but this molecule, designed to fight lung cancer, will soon enter the final phase of clinical trials.

So if Pfizer's takeover is successful, MEDI4736 will have yet another new owner.

No surprise, the staff of MedImmune - and the politicians supporting them in Maryland - are as worried about the implications of the Pfizer bid as AstraZeneca's people are here in the UK.

The business secretary refused to be drawn on the precise legal and financial mechanisms that could make Pfizer's assurances binding. He said he would "rather not expose" the government's thinking on that "in too much detail".

But he accepted that the government faced a "dilemma" between being open to the benefits of foreign investment and protecting wider national interests.

In response, Labour's shadow business secretary, Chuka Umunna, said he was still to be convinced that an acquisition would be good for the UK.

"I think what we heard at the hearing today reinforces the grave concerns we have about this deal and confirms many of the worst fears of many in the business and science community in the UK," he said.

"What do we know? [Pfizer] confirmed that they will be cutting jobs, they've confirmed that there will be a cut in the spending of the combined merged entity, they've confirmed that the business, AstraZeneca, will be split up, and they haven't ruled out selling off parts of it in the future."

And he pointed to AstraZeneca's assertion that the distraction of any deal could potentially inhibit the production of life-saving drugs.

But business body the Institute of Directors, said "we should be alive to the consequences of mounting a British Inquisition for those who wish to do business in what is supposed to be an open economy".

"If our politicians really want to whip up a storm around this issue, they'd be better off scrutinising the role of institutional investors in the whole process," added the body's director general Simon Walker.

"In particular, the asset managers and asset owners that control so many of AstraZeneca's shares."

Vince Cable says Pfizer faces "hurdles" before the takeover becomes binding

Earlier, Mr Read mounted a strong defence of Pfizer's record, rejecting complaints that it had a poor track record on maintaining jobs and investments, both in the UK and elsewhere.

Adrian Bailey, chairman of the Business Committee, asked Mr Read to respond to claims that Pfizer was like a "praying mantis" and a "shark that needs feeding".

Mr Read said he was "very proud" of his 35 years at the firm, describing it as a "company of high integrity focused on patients and delivering drugs to patients".

He said he was not concerned about an attack on the company by Swedish Prime Minister Fredrik Reinfeldt, who referred to "negative experiences" after Pfizer took over Pharmacia.

Mr Read said the comments were based on a "misunderstanding of the facts" over strategy and a promise to build a factory only if a product got regulatory approval. "Having set the facts right, I'm not concerned" by the comments, he said.

He added that a merged Pfizer-Astra would mean research expenditure would be lower than that of the two separate companies. This, he said, was because one of the drivers of the proposed deal was to increase efficiency in order to keep both firms competitive in an increasingly tough marketplace.

"Our commitment is to base 20% of our global research and development in the UK," he said. But without more due diligence on AstraZeneca's books "I can't tell you today how many people we are going to have in R&D," he added.

But the final jobs number would be "substantial", Mr Read promised. "I have not seen AstraZeneca's books. Some things are sight-unseen. But the numbers will be substantial... We are a highly ethical company. Pfizer is a company that keeps its promises."

Pfizer logo Pfizer has outlined its takeover proposals to AstraZeneca's shareholders

Committee member Mike Crockart asked why the UK Government should support a Pfizer bid, when "you have a reputation of being ruthless cost-cutters, and that seems to be borne out by what you have said today".

Mr Read replied that the takeover was "an opportunity to domicile the largest pharmaceutical company in the world, to bring the strength of the combined portfolios and to bring our financial strength into the UK and globally.

"I think it will strengthen the scientific base in the UK, a company our size making these sorts of commitments."

'Not long enough'

Before the committee hearing, the President of the Royal Society, Prof Sir Paul Nurse, told the BBC that Pfizer's five-year commitment to maintain research and jobs was "vague" and insufficient.

Sir Paul, who has submitted written evidence to the committee, said: "Research is a long-term business. I have researched for 40 years of my life. I know that five years is not long enough term to be committed to.

"They need to look at a 10-year horizon at least if they are actually going to make an important impact on this area and produce the medicines that will help people."

On Tuesday, Pfizer turned up the pressure on AstraZeneca by outlining its takeover proposals to Astra's shareholders.

Pfizer laid out the "strong strategic rationale" of the £63bn takeover plan.

Astra responded by calling Pfizer's takeover plan an "opportunistic attempt" to buy the company for a price that did not reflect the value of its "exciting pipeline" of new drugs.

Any deal would be the largest foreign takeover of a UK firm to date, but the proposal has revived memories of when US food giant Kraft abandoned jobs pledges after it bought Cadbury.

graphic about company size
 

More on This Story

Related Stories

Comments

This entry is now closed for comments

Jump to comments pagination
 
  • rate this
    +21

    Comment number 683.

    I worked for a company that merged with another. It was a complete disaster. I totally appreciate what the CEO of AstraZeneca was saying about disruption to the business.

  • rate this
    +25

    Comment number 660.

    My guess is that a large proportion of the people in this country are stakeholders in AZ through pension and other savings schemes. So they all have a valid opinion. Do they want to see R&D (=skilled workers) possibly move from this country and fewer companies (=less competition) supplying drugs to the NHS? Capitalism needs to benefit the whole country not just a single company.

  • rate this
    +22

    Comment number 624.

    It is obvious from some comments that the sole criteria for a takeover is making a quick buck. When UK no longer makes anything of significance where will investors go? Will major retail and insurance produce enough profit to suit more investors? If the purpose of investment is a quick buck rather than any sense of a long term strategy then the future for UK business is bleak.

  • rate this
    -76

    Comment number 105.

    there's a huge contradiction from the left on this. The left generally hate big business and hate pharmaceutical companies who they see as profiting from sick people. fair enough. but then you cant complain when the industry is driven down a path where R&D costs so much and new medicines don't get adopted by the NHS. job losses / mergers are inevitable

  • rate this
    +28

    Comment number 62.

    Either so many British businesses are badly mismanaged & unfit to survive, meaining takeovers are inevitable, or we have worthwhile industries needing proper managment & investment. The latter means there are still viable industries = proper employment for Brits, or the UK just goes to the wall & there's nothing left but shop work & fruit & veg picking. You choose.

 

Comments 5 of 10

 

More Business stories

RSS

Business Live

  1.  
    11:24: PwC probe

    The Financial Reporting Council isn't just investigating PwC over its involvement in Tesco. It also says today it will look at the accountant's work with Barclays following the bank's fine of £38m for putting £16.5bn of client assets at risk.

     
  2.  
    Cranking up Lada Via Email Theo Leggett Business reporter, BBC News

    "The Kremlin may be seeking to restore Russian pride in Lada - but it's relying on foreign investment to do it. The brand's parent, Avtovaz, is majority owned by the Renault-Nissan alliance - so these days its Russian identity has distinctly Franco-Japanese overtones. Oh, and last week, Renault-Nissan CEO Carlos Ghosn said the falling rouble was causing a "bloodbath" in the Russian car industry."

     
  3.  
    10:56: Tesco inquiry Kamal Ahmed BBC Business editor

    "The fact that the inquiry will investigate three years of accounts will concern investors as it could reveal further evidence that the problems go back further than initially thought. The FRC's arsenal if any wrong-doing is found is formidable. It can impose unlimited fines on PwC, it can demand unlimited costs and it can strike off any individual found to have behaved improperly."

     
  4.  
    10:46: Banking's reputation

    The Bank of England has urged banks to go further than "stress testing" to regain their customers' confidence. This from the latest Financial Policy Committee minutes: "Committee members also noted that recent misconduct and other operational failings had highlighted that rebuilding confidence in the banking system would require more than financial resilience... The Committee judged that strong, effective and well-informed management and governance arrangements would be essential to rebuild confidence in the banking system."

     
  5.  
    Via Twitter James Cook Scotland Correspondent, BBC News

    "Shoppers rescued from flooded Asda in Kilmarnock"

    East Ayrshire Police
     
  6.  
    10:20: Tesco inquiry

    Our business editor points out that the Financial Reporting Council only has power over its members - i.e. auditors, which in Tesco's case were PwC. However, the FRC can ask Tesco to assist in the investigation.

     
  7.  
    Via Twitter Kamal Ahmed BBC Business editor

    "FRC's inquiry will include PWC's auditing of Tesco's accounts as well as the preparation of those accounts"

     
  8.  
    Breaking News
  9.  
    09:55: Scotland's budget
    North Sea Oil

    The lead in the Financial Times is a suggestion that Scotland may have been saved from a crisis in its public finances by voting "no" in the referendum on independence. It says projections by the Office for Budget Responsibility suggest that had Scotland voted "yes", the falling oil prices would have led to its North Sea oil revenues slumping to just one-fifth of Holyrood's preferred forecasts in the country's first year of independence.

     
  10.  
    09:40: Snow-plough parents
    Skiing

    The Times highlights what it says is a new trend for well-heeled British parents: hiring private tutors to accompany them on family skiing trips. This apparently allows teenagers to cram for forthcoming exams, while still enjoying some action on the piste. The paper says it brings fresh meaning to the term "snow-plough parents" - those over-protective parents, bent on removing every obstacle in their offspring's path.

     
  11.  
    09:25: Spanish tax
    Cristina

    A judge in Spain has ordered that Princess Cristina de Borbon, the sister of the Spanish King, be tried on charges of tax fraud. It will be the first time a member of the Spanish royal family appears in the dock.

     
  12.  
    09:10: Facebook friends Russia
    Navalny

    On its front page, The Independent reports that Facebook has been accused of giving in to censorship after it apparently blocked access to a protest page on its site - under pressure from the Kremlin. A former US ambassador to Russia describes it as a "horrible precedent". According to The Daily Telegraph, Facebook has declined to comment on the suggestion that it stopped Russian users from viewing a page, rallying support for one of President Putin's most prominent opponents.

     
  13.  
    08:55: UK jobs Radio 5 live

    The employers' organisation, the CBI, says its latest survey suggests that half of its members plan to take on more staff next year. "Skills are at a premium in lots of areas," says CBI's director for employment and skills, Neil Carberry. "In fact one of the things we found in this year's survey is the biggest worry now for companies in their broadly rosy picture is whether they can get the skills they need to keep growing."

     
  14.  
    08:45: Markets update

    The main European markets are all looking rather chirpy this morning. Gains for oil firms, including Tullow Oil, Royal Dutch Shell and BP are driving the FTSE up 1% to 6,608. That's partly because Brent Crude has risen by 2% to $62.24 a barrel. In Germany, the Dax is up 0.9% to 9872, while in France, the Cac-40 is up 1.2% to 4293.

     
  15.  
    Cranking up Lada 08:28: Via Email Tony Higgins Lada owner

    "We had a Lada Niva. We bought it when we moved to a Lancashire hill farm in 1993. It was great. The early years were bad winters but the Lada coped very well. It was like a crab both on and off road, permanent 4WD. No power steering so hard work."

     
  16.  
    08:12: Pull over, Uber
    Xiaomi

    Uber may have been valued at $40bn, but one Chinese tech firm could now be worth an estimated $45bn, despite being relatively unknown outside Asia. The WSJ reports that smartphone and tablet maker Xiaomi, whose polished branding and devoted fan base is reminiscent of Apple's, has overtaken Samsung in China, but faces several challenges in expanding into India and beyond.

     
  17.  
    07:54: Cranking up Lada

    So, on to some of those Lada jokes. What do you call a Lada with a sun roof? A skip. What do you call a Lada with a sunroof and twin exhausts? A wheelbarrow. Etc. Send us your favourite Lada jokes: bizlivepage@bbc.co.uk and we will publish the best. Or if you've driven a Lada, and think they get a bad rap, let us know.

     
  18.  
    07:49: Cranking up Lada
    Lada

    The New York Times reports that the Kremlin is seeking to revive Russia's last major Soviet brand - the carmaker Lada. It has recruited Swedish-American Bo Inge Andersson, previously a vice president at General Motors. Lada, historically the butt of many jokes, still accounts for a third of all cars in Russia, and as foreign companies like Audi and Jaguar Land Rover suspend sales in the country due to the plummeting rouble, the utilitarian company could return to strength.

     
  19.  
    07:35: B&Q China
    bnq

    Kingfisher says it will flog its controlling 70% stake in B&Q China to Wumei Holdings for £140m. It opened its first B&Q in the country in 1999.

     
  20.  
    07:25: Oil blessing?

    The Guardian's leader takes a contrarian stance on falling oil prices, which have been widely welcomed by Western consumers. "Oil has dipped 40%, pessimists fear, because the world no longer expects a return to economic full pelt," it argues. "Europe, Japan and - relative to its own vigorous standards - China, have all been looking anaemic this year. Like low blood pressure after a heart attack, then, cheap oil should arguably be regarded not as a sign of rude health, but rather as a consequence of malaise."

     
  21.  
    07:12: Budget Samsung
    Samsung

    $100 for a Samsung smartphone? CNBC reports the South Korean company is entering the increasingly competitive budget handset market, in a bid to sell more phones in India, where many people still use simple phones. The new handset will run Samsung's own Tizen software.

     
  22.  
    06:58: Rates Radio 5 live

    The Bank of England's Martin Weale adds that he is optimistic about the year ahead. More money to spend from cheaper oil will help. He's on the committee that helps decide the key interest rate. Will it rise this year? He's careful not to second-guess his colleagues on that one.

     
  23.  
    06:46: Santa rally? Radio 5 live
    santa

    Will there be a so-called Santa rally this year? A rise in markets in the days around Christmas? Brenda Kelly from IG says you see one in almost nine out of every 10 years since the '80s.

     
  24.  
    06:28: Rates Radio 5 live

    The Bank of England's Martin Weale has been telling Wake Up to Money why he's been voting for interest rates to move off the record low of 0.5%. "It isn't only that unemployment has been falling - at least until recently extremely rapidly. It's also that when I go and visit businesses throughout the country I find they're talking of pay increases in a way quite different from what I was hearing early in the year certainly this time last year."

     
  25.  
    06:16: Markets Radio 5 live

    Brenda Kelly from IG is Wake Up to Money's markets guest. They are talking about the falling oil prices. "A lot of it is down to a glut of supply and Saudi Arabia wants to keep market share," she says. Saudi's breakeven price is only a few dollars per barrel.

     
  26.  
    06:10: Christmas spending Radio 5 live

    Mark Barnett, UK & Ireland president of Mastercard, is on Wake Up to Money, talking about Christmas shopping habits. What else? People have returned to luxury goods, he said. Holidays and furniture are down a little bit though.

     
  27.  
    06:04: Hacking 2.0
    Kim Jong

    The global cyberwar that dominated headlines last week shows no signs of abating. Hackers have infiltrated South Korea's nuclear power provider, and posted schematics of nuclear reactors and private personal records online. It's not clear whether the same group that attacked Sony Pictures is responsible.

     
  28.  
    06:00: Howard Mustoe Business reporter

    Morning! Get in touch. Tell us what you think. Email bizlivepage@bbc.co.uk or on Twitter @BBCBusiness

     
  29.  
    06:00: Joe Miller Business Reporter

    Good morning, and festive greetings all round. In a week when the business world is winding down for Christmas, we'll bring you all the news that's sneaking in the back door, and much more besides.

     

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.